Summary
Amgen Inc.'s first quarter 2001 results show robust growth, with total revenues increasing by 11% to $901.6 million, driven primarily by strong product sales. Net income rose to $304.9 million, or $0.28 per diluted share, up from $266.2 million, or $0.25 per diluted share, in the prior year's comparable period. The company highlighted significant year-over-year increases in both EPOGEN® and NEUPOGEN® sales, demonstrating continued demand for its key biopharmaceutical products. Despite increased investments in research and development and selling, general, and administrative expenses, Amgen maintained healthy operating income and cash flow from operations.
Key Highlights
- 1Total revenues increased by 11% to $901.6 million for the three months ended March 31, 2001, compared to $814.1 million in the prior year period.
- 2Net income grew by approximately 15% to $304.9 million, with diluted EPS increasing to $0.28 from $0.25.
- 3Product sales, driven by EPOGEN® and NEUPOGEN®, saw a 14% increase to $798.4 million.
- 4EPOGEN® sales grew 14% to $503.1 million, attributed to increased patient populations and pricing.
- 5NEUPOGEN® sales increased 18% to $294.0 million, benefiting from prior year inventory adjustments and current year demand.
- 6The company's cash position strengthened significantly, with cash and cash equivalents increasing to $478.9 million from $226.5 million at the end of 2000.
- 7Amgen has revised its 2001 guidance for total product sales growth to a low-double digit rate and EPS growth to a low-double digit rate, reflecting a more conservative outlook.
Frequently Asked Questions
Revenue growth was primarily driven by strong performance in product sales, which increased by 14% year-over-year. Specifically, EPOGEN® sales grew by 14% due to increased demand from the dialysis patient population and higher prices, while NEUPOGEN® sales saw an 18% increase, benefiting from prior year inventory adjustments and current demand.
Amgen demonstrated improved profitability, with net income increasing by approximately 15% to $304.9 million in the first quarter of 2001, up from $266.2 million in the same period of 2000. Diluted earnings per share also rose to $0.28 from $0.25.
Amgen expects combined sales growth for EPOGEN® and the anticipated launch of ARANESP™ to be in the low-teens for 2001, a revision from previous higher guidance. This adjustment is due to a longer FDA approval timeline for ARANESP™, lower-than-expected U.S. dialysis patient population growth, and potential impacts from federal reimbursement policies.
Amgen's cash position significantly improved, with cash and cash equivalents rising to $478.9 million. The company generated $315.4 million in cash from operating activities and has substantial liquidity from its cash, cash equivalents, and marketable securities totaling $2,292.4 million. Amgen also has access to debt financing, including a commercial paper program and a credit facility.